• Explore /
  • Poster
  • / Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.

Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.

Abstract Poster

Authors

null

Katherine Fan

Johns Hopkins University School of Medicine

Katherine Fan , Aaron Wild , Daniel Laheru , Timothy Pawlik , Lei Zheng , Dung Le , Phuoc Tran , Avani Dholakia , Rachit Kumar , Susannah Ellsworth , Amy Hacker-Prietz , Zeshaan Rasheed , Ana De Jesus-Acosta , Matthew Weiss , Martin Makary , John Cameron , Ralph Hruban , Elliott Fishman , Christopher Wolfgang , Joseph Herman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00962520

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr269)

DOI

10.1200/jco.2013.31.4_suppl.269

Abstract #

269

Poster Bd #

C17

Abstract Disclosures

Similar Posters

First Author: Janet E. Murphy

First Author: Dirk Strumberg

First Author: M. M. Javle

Poster

2022 ASCO Gastrointestinal Cancers Symposium

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.

First Author: Choong-kun Lee